LONDON, UK, October 15, 2025 / Biotech Newswire / -- Touchlight, a leader in synthetic DNA manufacturing, announced today the use of its proprietary z- dbDNA™ technology as a critical starting material in the manufacture of a cutting-edge gene therapy in a US-based clinical study.
This development underscores the transformative potential of dbDNA in driving the development of safe, effective, and scalable therapies. It follows Touchlight’s receipt in 2025 of a GMP certificate for the production of dbDNA at its state-of-the-art facility in Hampton, UK. dbDNA’s unique design, a linear, closed-end DNA construct free of bacterial sequences, ensures high purity and stability, making it an ideal platform for gene therapy applications.
The senior scientist working on this clinical study, said: “Touchlight’s z- dbDNA platform provided the high-purity DNA material, scalable production capabilities, and rapid turnaround necessary to advance our gene therapy program. The team demonstrated technical responsiveness and a solution-driven approach, facilitating sequence delivery and production support within a compressed timeline. Communication was consistently clear, and batch release testing met all delivery and quality expectations”.
Unlike conventional plasmid DNA, dbDNA is manufactured using a cell-free process that is faster and more scalable, whilst eliminating the risk of antibiotic resistance or other unwanted contaminants. These characteristics of dbDNA align with regulatory guidelines and the growing need for safer, more efficient biomanufacturing processes.
Touchlight remains committed to empowering researchers and biopharmaceutical companies with the tools they need to push the boundaries of genetic medicine. The company’s ongoing collaborations and innovations continue to support the development of life-changing therapies for patients worldwide.
For high resolution please click the image.
About Touchlight
Touchlight is a leading innovation-driven CDMO pioneering enzymatic GMP DNA production to enable the genetic medicine revolution. Founded in 2007 and inspired by breakthroughs in genetic medicine, Touchlight’s team has built a business and technology platform which recognised and addresses the urgent need for innovative DNA production techniques to support the future of genetic therapies.
As sector leaders, with an FDA Drug Master File accepted in 2022 and having been awarded the world’s first cell-free DNA GMP license in 2025, Touchlight’s enzymatic DNA technology is at the cutting edge for AAV, mRNA, DNA vaccine, and gene editing technologies.
Touchlight’s state-of-the-art facility was recognised in 2025 by ISPE’s Facility of the Year Awards (FOYA) for Innovation.
With multiple client products already in the clinic, Touchlight’s proven synthetic DNA manufacturing solutions offer a scalable, sustainable alternative to plasmid DNA (pDNA) for all stages of pre-clinical, clinical and commercial development.
The business and technology of Touchlight are built on the conviction that DNA is fundamental to the future of medicine. Traditional methods, based on bacterial fermentation, are generally considered to be slow, costly and unable to meet the growing demands of genetic medicine due to limited scalability and speed.
Contact
Touchlight
Karen Fallen, Chief Executive Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
+44 20 8481 9200
Keywords: Plasmids; DNA; Genetic Therapy; Technology; Nucleic Acids; Gene Editing; United Kingdom; Touchlight; z-dbDNA technology; synthetic DNA manufacturing; gene therapy; dbDNA; GMP certificate; bacterial sequence-free DNA; high purity DNA; gene therapy applications; scalable DNA production; batch release testing; plasmid DNA alternative; cell-free DNA manufacturing; antibiotic resistance-free DNA; biomanufacturing; regulatory compliance; genetic medicine; CDMO (Contract Development and Manufacturing Organization); enzymatic GMP DNA production; cell-free DNA GMP license
Source: Biotech Newswire